Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group
- PMID: 10169531
Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group
Abstract
This 6-month, randomized, multicenter study was designed to determine whether patients who had been treated with the leukotriene pathway inhibitor zileuton 600 mg four times daily (QID) for 2 months could be maintained at the same level of pulmonary function, symptom control, and beta-agonist use with less frequent dosing--first 600 or 800 mg three times daily (TID) and then twice daily (BID). A total of 278 patients with chronic asthma, ages 16 to 70, participated at 25 US centers. All had a 1-second forced expiratory volume (FEV1) of 35%-75%, reversible airway disease, and a nonsmoking history of 1 year. An 8-week open-label period (zileuton 600 mg QID) was followed by a 16-week double-blind period, in which patients who responded to the QID treatment were randomized to receive zileuton 600 or 800 mg TID for 8 weeks and then rerandomized to receive zileuton 600 or 800 mg BID for another 8 weeks. Primary outcomes were FEV1 and asthma symptom scores; secondary outcomes were peak expiratory flow rate, beta-agonist use, and asthma exacerbations requiring steroid rescue. Patients who showed improvements in lung function when treated with zileuton 600 mg QID demonstrated minimal decreases in FEV1 and comparable peak expiratory flow rates, symptom control, beta-agonist use, and systemic corticosteroid rescue when being treated with lower doses and/or less frequent doses of zileuton. Patients who demonstrate improved asthma control with zileuton 600 mg QID may be able to reduce their daily dosage and/or frequency while still maintaining the same level of symptom control.
Similar articles
-
Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group.JAMA. 1996 Mar 27;275(12):931-6. JAMA. 1996. PMID: 8598621 Clinical Trial.
-
Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group.J Allergy Clin Immunol. 1996 Nov;98(5 Pt 1):859-71. doi: 10.1016/s0091-6749(96)80002-9. J Allergy Clin Immunol. 1996. PMID: 8939149 Clinical Trial.
-
Safety and clinical efficacy of zileuton in patients with chronic asthma.Am J Manag Care. 1998 Jun;4(6):841-8. Am J Manag Care. 1998. PMID: 10181070 Clinical Trial.
-
Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma.Ann Pharmacother. 1996 Jul-Aug;30(7-8):858-64. doi: 10.1177/106002809603000725. Ann Pharmacother. 1996. PMID: 8826571 Review.
-
Treatment of chronic stable asthma with drugs active on the 5-lipoxygenase pathway.Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):319-20. doi: 10.1159/000237013. Int Arch Allergy Immunol. 1995. PMID: 7613158 Review.
Cited by
-
Mutations in the human 5-lipoxygenase gene.Clin Rev Allergy Immunol. 1999 Spring-Summer;17(1-2):59-69. doi: 10.1007/BF02737597. Clin Rev Allergy Immunol. 1999. PMID: 10436859
-
Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers.Mol Diagn Ther. 2007;11(2):97-104. doi: 10.1007/BF03256228. Mol Diagn Ther. 2007. PMID: 17397245 Review.
-
The phosphatidylinositide 3-kinase (PI3K) signaling pathway is a determinant of zileuton response in adults with asthma.Pharmacogenomics J. 2018 Sep;18(5):665-677. doi: 10.1038/s41397-017-0006-0. Epub 2018 Jan 3. Pharmacogenomics J. 2018. PMID: 29298996 Free PMC article.
-
Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production.J Clin Invest. 2005 Jun;115(6):1601-6. doi: 10.1172/JCI23949. J Clin Invest. 2005. PMID: 15931391 Free PMC article.
-
Genome-wide association study of leukotriene modifier response in asthma.Pharmacogenomics J. 2016 Apr;16(2):151-7. doi: 10.1038/tpj.2015.34. Epub 2015 Jun 2. Pharmacogenomics J. 2016. PMID: 26031901 Free PMC article. Clinical Trial.
